The short answer
Most of the literature is indexed under thymosin beta-4 rather than TB-500, because TB-500 is a supplier-facing development code rather than a term used in research papers. Searching only for TB-500 misses nearly all of it.
Key facts
- Primary search term
- Thymosin beta-4
- Also useful
- Tβ4, beta-thymosins, LKKTETQ
- TB-500 in PubMed
- Rare (it is a trade-side code)
- Key review
- Hannappel, Ann N Y Acad Sci 2007
- Foundational
- Low, PNAS 1981
- Evidence type
- Predominantly preclinical
Why searching for TB-500 fails
TB-500 is a development code that became a product name. Researchers publishing on the molecule write about thymosin beta-4 or its fragments, and index terms follow the science rather than the market. Anyone searching PubMed for TB-500 will find very little and may conclude the literature is thin, when in fact it is substantial under a different name.
What to search instead
Thymosin beta-4 is the primary term. Beta-thymosins covers the wider family. LKKTETQ finds work specifically on the motif, which is the closest match to the fragment itself. Searching all three gives a fair picture, and comparing what each returns is itself informative about how much work concerns the protein versus the peptide.
Research material referenced
TB-500 5mg, third-party HPLC tested
The two anchors
Low and colleagues' 1981 PNAS paper established the complete bovine sequence. Hannappel's 2007 review in the Annals of the New York Academy of Sciences covers the beta-thymosin family and is the sensible orientation point for anyone new to the area. Goldstein's 2012 review in Expert Opinion on Biological Therapy covers the regenerative literature.
The question to ask of every paper
Which molecule was administered. Full-length thymosin beta-4 and the LKKTETQ heptapeptide are both in the literature, and papers state which. Given that the commercially interesting findings and the fragment-attributable findings are largely different sets, this single check does more to clarify the evidence than any other.
What the shape of the literature tells you
Decades of work, concentrated in cell biology and preclinical models, with limited human clinical data and no established registered trial programme for the heptapeptide. That is a mature basic-science literature rather than a therapeutic development programme, and reading it as the latter overstates where it has got to.
Frequently asked questions
Why does PubMed return so little for TB-500?
It is a development and trade code rather than a term used in research papers. The literature is indexed under thymosin beta-4.
Which paper is the best starting point?
Hannappel's 2007 review in the Annals of the New York Academy of Sciences for orientation; Low 1981 in PNAS for the foundation.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedLow TL et al., Complete amino acid sequence of bovine thymosin beta 4. PNAS 1981 (PMID 6940133)pubmed.ncbi.nlm.nih.gov
- PubMedHannappel E, beta-Thymosins: Ann N Y Acad Sci 2007 (PMID 17468232)pubmed.ncbi.nlm.nih.gov
- PubMedGoldstein AL et al., Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012 (PMID 22074294)pubmed.ncbi.nlm.nih.gov
- PubMedShrivastava S et al., Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010 (PMID 20536454)pubmed.ncbi.nlm.nih.gov
- PubMedSosne G et al., Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002 (PMID 11950239)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- PubChemPubChem · Thymosin β4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More TB-500 (Thymosin β4 fragment) articles
- Fragment Research: The Logic and Its LimitsIsolating a motif attributes an effect to that motif. What that buys, what it costs, and why fragment results do not automatically transfer to the parent.
- What Does TB-500 Stand For?TB is thymosin beta; 500 is a development series number carrying no chemical meaning. Why a code name became a product name, and what that obscures.
- TB-500: Names, Spellings and What Each FindsTB-500, TB500, Tβ4, thymosin beta-4, LKKTETQ. Which term finds the science, which finds the market, and why they return different things.
- BPC-157 and TB-500 Together: What the Evidence SaysThe two are frequently combined commercially, including in blends. Whether the research literature supports studying them together is a separate question.
- TB-500 Side Effects: No Human Safety Record ExistsNo controlled human study has been published. What the rodent work reports, the concern that follows from promoting cell migration, and what is unmeasured.